MACULAR PHOTOCOAGULATION STUDY

黄斑光凝研究

• 批准号: 3551581
• 负责人: GARY FISH
• 金额: $ 4.25万
• 依托单位: TEXAS RETINA ASSOCIATES, INC.
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-09-30 至 1990-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3551581
• 关键词: aging; disease /disorder prevention /control; eye laser surgery; eye surgery; human subject; human therapy evaluation; patient /disease registry; photocoagulation therapy; retina degeneration; vision tests

The proposed Foveal Photocoagulation Study is a multicenter study of treatment for age-related macular degeneration (AMD) in eyes with subfoveal neovascular lesions. The study consists of two randomized controlled trials of laser photocoagulation treatment and a natural history study of eyes ineligible for the trials. Eligible AMD patients who meet the visual acuity criteria for the randomized trials (20/80 vA 20/320) will be assigned to treatment or to no treatment of the neovascular lesion. Nature history study patients will have AMD and a subfoveal neovascular lesion but visual acuity better than 20/80. The purpose of the randomized trials is to determine whether krypton red laser photocoagulation is effective in preventing or delaying severe loss of vision in AMD patients who have subfoveal lesions, whether there are new neovascular lesions or recurrent neovascularization subfoveally following prior treatment for extrafoveal or juxtafoveal lesions. The purpose of the natural history study is to determine the rate at which visual acuity deteriorate to 20/80 or worse in eyes with AMD and subfoveal neovascular membranes after initial clinical presentation of patients who would otherwise be eligible for the randomized trials. The study will be carried out in twelve Clinical Centers, a Coordinating Center, and a Fundus Photograph Reading Center; the study investigators and centers consist primarily of those who have collaborated in the Macular Photocoagulation Study (MPS) over the past six years.

拟议的中心凹光凝研究是一项多中心研究， 治疗具有中心凹下的眼睛中的年龄相关性黄斑变性（AMD） 新生血管病变 该研究包括两个随机对照组， 激光光凝治疗的试验和 眼睛不适合试验。 符合视力要求的合格AMD患者 随机试验的急性标准（20/80 vA 20/320）将是 分配到治疗或不治疗新生血管病变。 性质 历史研究患者将患有AMD和中心凹下新生血管病变， 视力高于20/80。 随机试验的目的是确定氪红 激光光凝可有效预防或延迟严重的损失 有黄斑下病变的AMD患者的视力，是否有新的 新生血管病变或复发性新生血管形成 对中心凹外或中心凹旁病变的既往治疗。 的目的 自然史研究是为了确定视力 在AMD和中心凹下新生血管的眼睛中恶化至20/80或更差 膜后，最初的临床表现的患者， 否则将有资格参加随机试验。 该研究将在12个临床中心进行，协调中心 中心和眼底照片阅读中心;研究者和 中心主要由那些谁在黄斑合作 过去6年的光凝研究（MPS）。